Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy

Shivi Agrawal, Malav Joshi, John B Christoforidis

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Vascular endothelial growth factor (VEGF) is a potent promoter of angiogenesis involved in a wide variety of physiologic processes. Intravitreal injections targeting VEGF have transformed the treatment of neovascular retinal diseases. Currently, there are four anti-VEGF agents in use: bevacizumab, ranibizumab, pegaptanib, and aflibercept. The success and frequency of anti-VEGF therapy have made the ocular safety profile of these agents of vital importance. This paper focuses on sterile endophthalmitis. In this paper, we compare the incidences of posttreatment sterile endophthalmitis among the four agents, review the mechanism of actions, and discuss the most prevalent hypotheses leading to sterile endophthalmitis.

Original languageEnglish (US)
Article number943409
JournalMediators of Inflammation
Volume2013
DOIs
StatePublished - 2013

Fingerprint

Vascular Endothelial Growth Factor A
Endophthalmitis
Inflammation
Drug Therapy
Retinal Diseases
Intravitreal Injections
Safety
Incidence
Therapeutics

ASJC Scopus subject areas

  • Cell Biology
  • Immunology

Cite this

Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy. / Agrawal, Shivi; Joshi, Malav; Christoforidis, John B.

In: Mediators of Inflammation, Vol. 2013, 943409, 2013.

Research output: Contribution to journalArticle

@article{4f74c0f20b1e46559fb6ac96f2f9f3d2,
title = "Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy",
abstract = "Vascular endothelial growth factor (VEGF) is a potent promoter of angiogenesis involved in a wide variety of physiologic processes. Intravitreal injections targeting VEGF have transformed the treatment of neovascular retinal diseases. Currently, there are four anti-VEGF agents in use: bevacizumab, ranibizumab, pegaptanib, and aflibercept. The success and frequency of anti-VEGF therapy have made the ocular safety profile of these agents of vital importance. This paper focuses on sterile endophthalmitis. In this paper, we compare the incidences of posttreatment sterile endophthalmitis among the four agents, review the mechanism of actions, and discuss the most prevalent hypotheses leading to sterile endophthalmitis.",
author = "Shivi Agrawal and Malav Joshi and Christoforidis, {John B}",
year = "2013",
doi = "10.1155/2013/943409",
language = "English (US)",
volume = "2013",
journal = "Mediators of Inflammation",
issn = "0962-9351",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy

AU - Agrawal, Shivi

AU - Joshi, Malav

AU - Christoforidis, John B

PY - 2013

Y1 - 2013

N2 - Vascular endothelial growth factor (VEGF) is a potent promoter of angiogenesis involved in a wide variety of physiologic processes. Intravitreal injections targeting VEGF have transformed the treatment of neovascular retinal diseases. Currently, there are four anti-VEGF agents in use: bevacizumab, ranibizumab, pegaptanib, and aflibercept. The success and frequency of anti-VEGF therapy have made the ocular safety profile of these agents of vital importance. This paper focuses on sterile endophthalmitis. In this paper, we compare the incidences of posttreatment sterile endophthalmitis among the four agents, review the mechanism of actions, and discuss the most prevalent hypotheses leading to sterile endophthalmitis.

AB - Vascular endothelial growth factor (VEGF) is a potent promoter of angiogenesis involved in a wide variety of physiologic processes. Intravitreal injections targeting VEGF have transformed the treatment of neovascular retinal diseases. Currently, there are four anti-VEGF agents in use: bevacizumab, ranibizumab, pegaptanib, and aflibercept. The success and frequency of anti-VEGF therapy have made the ocular safety profile of these agents of vital importance. This paper focuses on sterile endophthalmitis. In this paper, we compare the incidences of posttreatment sterile endophthalmitis among the four agents, review the mechanism of actions, and discuss the most prevalent hypotheses leading to sterile endophthalmitis.

UR - http://www.scopus.com/inward/record.url?scp=84888994584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888994584&partnerID=8YFLogxK

U2 - 10.1155/2013/943409

DO - 10.1155/2013/943409

M3 - Article

C2 - 24307762

AN - SCOPUS:84888994584

VL - 2013

JO - Mediators of Inflammation

JF - Mediators of Inflammation

SN - 0962-9351

M1 - 943409

ER -